Submission of Transcripts for the Earnings Call held on May 20 2026 to discuss the Financial and Operational Performance for Q4FY26
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.7 pts less than its Plastic Products - Consumer peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shaily Engineering Plastics reported strong Q4 FY26 results with revenue of INR 237 crores (up 9% YoY), EBITDA of INR 69 crores (up 27% YoY) with margins expanding 420 bps to 29.3%, and PAT of INR 40 crores (up 40% YoY). For FY26, revenue grew 26% to INR 991 crores, EBITDA surged 61% to INR 288 crores with 29% margins (up 630 bps), and PAT jumped 83% to INR 170 crores. The healthcare segment was a standout performer, with FY26 revenue nearly tripling to INR 393 crores (40% of consolidated revenue vs 21% last year). Key milestones include commercial launch of Semaglutide pen injectors in Canada, first tentative US approval, and new business from consumer electronics and semiconductor trays. The company approved an enabling resolution to raise up to INR 500 crores for future growth opportunities.
The strong margin expansion and healthcare growth trajectory indicate successful execution of the diversification strategy away from consumer/home furnishings. New verticals in semiconductors and consumer electronics provide additional growth levers, while the INR 500 crore fundraise approval positions the company to capture large capital-intensive opportunities.